Thomas M. Maier

Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group

Thomas Beckers, Carmen Burkhardt, H. Wieland et al. · International Journal of Cancer · 2007 · 194 citations · Full text

Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity

Siavosh Mahboobi, Andreas Sellmer, Mathias Winkler et al. · Journal of Medicinal Chemistry · 2010 · 96 citations · Full text

Histone Modifications, Chromatin, Medicine +13

Design of Chimeric Histone Deacetylase- and Tyrosine Kinase-Inhibitors: A Series of Imatinib Hybrides as Potent Inhibitors of Wild-Type and Mutant BCR-ABL, PDGF-Rβ, and Histone Deacetylases

Siavosh Mahboobi, Stefan Dove, Andreas Sellmer et al. · Journal of Medicinal Chemistry · 2009 · 90 citations · Full text

Histone Deacetylases, Hdac Inhibitors, Tumor Biology +17

Amine‐Borane Dehydrogenation and Transfer Hydrogenation Catalyzed by α‐Diimine Cobaltates

Thomas M. Maier, Sebastian Sandl, Ilya G. Shenderovich et al. · Chemistry - A European Journal · 2018 · 75 citations

Inorganic Chemistry, Chemical Engineering, Bh 3 +10

Cobalt-Catalyzed Hydrogenations via Olefin Cobaltate and Hydride Intermediates

Sebastian Sandl, Thomas M. Maier, Nicolaas P. van Leest et al. · ACS Catalysis · 2019 · 65 citations · Full text

Inorganic Chemistry, Chemical Engineering, Engineering +12